Dengue is a mosquito-borne viral disease that occurs mainly in the tropics and subtropics but has a high potential to spread to new areas. Dengue infections are climate sensitive, so it is important to better understand how changing climate factors affect the potential for geographic spread and futu...re dengue epidemics. Vectorial capacity (VC) describes a vector's propensity to transmit dengue taking into account human, virus, and vector interactions. VC is highly temperature dependent, but most dengue models only take mean temperature values into account. Recent evidence shows that diurnal temperature range (DTR) plays an important role in influencing the behavior of the primary dengue vector Aedes aegypti. In this study, we used relative VC to estimate dengue epidemic potential (DEP) based on the temperature and DTR dependence of the parameters of A. aegypti. We found a strong temperature dependence of DEP; it peaked at a mean temperature of 29.3°C when DTR was 0°C and at 20°C when DTR was 20°C. Increasing average temperatures up to 29°C led to an increased DEP, but temperatures above 29°C reduced DEP. In tropical areas where the mean temperatures are close to 29°C, a small DTR increased DEP while a large DTR reduced it. In cold to temperate or extremely hot climates where the mean temperatures are far from 29°C, increasing DTR was associated with increasing DEP. Incorporating these findings using historical and predicted temperature and DTR over a two hundred year period (1901-2099), we found an increasing trend of global DEP in temperate regions. Small increases in DEP were observed over the last 100 years and large increases are expected by the end of this century in temperate Northern Hemisphere regions using climate change projections. These findings illustrate the importance of including DTR when mapping DEP based on VC.
more
This package, developed jointly by The ACQUIRE Project and Promundo, a Brazilian nongovernmental organization, can be used by individuals, organizations, and donors to carry out needs assessments to identify gaps in male engagement programming related to HIV and AIDS prevention, care, treatment, and... support.
more
Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021
Considerations on the implementation and adjustment of
public health and social measures in the context of
COVID-19
Interim guidance 14 June 2021
The role of community health workers in the vaccination against COVID-19: guide to support the implementation of the vaccination programme
Este relatório confere uma visão geral estado da epidemia HIV/SIDA em Moçambique e de como tem sido feita a resposta nacional à epidemia. Cobre também as boas práticas neste campo, tal como os principais desafios e acções correctivas.
SOBRE ESTE GUIA
Este é um guia de referência rápida que resume as recomendações da Superintendência de Atenção Primária (S/SUBPAV/SAP) para o diagnóstico e o manejo na atenção primária da infecção pelo novo coronavírus. O documento representa o posicionamento da S/SUBPAV/SAP e tem a... função de orientar a assistência clínica nas unidades de atenção primária na cidade do Rio de Janeiro. Em caso de condutas divergentes do que estiver presente neste guia, recomenda-se o devido registro da justificativa em prontuário. Por
ser um campo em constante mudança, este guia será atualizado regularmente, e a versão mais recente estará disponível no site da SUBPAV (www.subpav.org) e no site www.coronavirus.rio, com uma lista das atualizações e suas respectivas datas.
more
Discussion Paper "Mental health, poverty and development", July 2009
Since the description of the first case of COVID-19 in Wuhan, Hubei province in China, in December 2019, much knowledge has been accumulated about the dynamics of evolution of the SARS-CoV-2 virus, contagion, disease progression, prevention and treatment.
Este documento de referência foi preparado pelo Grupo de Trabalho sobre Vacinas contra COVID-19 do Grupo Consultivo Estratégico de Especialistas em Imunização (SAGE) para orientar as discussões do SAGE em sua reunião extraordinária de 8 de fevereiro de 2021, que resultou na publicação do do...cumento da OMS de 10 de fevereiro de 2021 Recomendações provisórias para o uso da vacina AZD1222 [ChAdOx1-S (recombinante)] contra COVID-19 desenvolvida pela Universidade de Oxford e pela AstraZeneca. Os dois documentos estão disponíveis na página sobre COVID-19 do SAGE: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials. Têm sido usados vetores de adenovírus deficientes na replicação contendo um transgene específico do patógeno como novas vacinas devido à sua capacidade de induzir respostas humorais e celulares fortes.
more